Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials - PubMed
4 days ago
- #Clinical Trial
- #Dupilumab
- #Chronic Spontaneous Urticaria
- Dupilumab was evaluated in the phase 3 LIBERTY-CSU CUPID-C trial for chronic spontaneous urticaria (CSU) uncontrolled by H1-antihistamines (H1-AH).
- The trial confirmed significant improvements in itch severity (ISS7) and urticaria activity (UAS7) with dupilumab vs placebo at week 24.
- Pooled data from CUPID-A and CUPID-C trials (289 participants) showed greater efficacy in reducing urticaria symptoms.
- Safety outcomes were consistent with dupilumab's known profile, with similar adverse event rates between dupilumab and placebo groups.
- Dupilumab is effective in anti-IgE-naive CSU patients unresponsive to H1-AH.